{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:29:49Z","timestamp":1794360589861,"version":"4.9.0"},"reference-count":234,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41573-023-00775-6","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T12:02:33Z","timestamp":1693483353000},"page":"917-934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Therapeutic approaches for Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-7631","authenticated-orcid":false,"given":"Thomas C.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J. A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-8520","authenticated-orcid":false,"given":"Kay E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"775_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","journal-title":"Cell"},{"key":"775_CR2","first-page":"83","volume":"40","author":"T Moriuchi","year":"1993","unstructured":"Moriuchi, T., Kagawa, N., Mukoyama, M. & Hizawa, K. Autopsy analyses of the muscular dystrophies. Tokushima J. Exp. Med. 40, 83\u201393 (1993).","journal-title":"Tokushima J. Exp. Med."},{"key":"775_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.amjcard.2016.01.031","volume":"117","author":"DY Chiang","year":"2016","unstructured":"Chiang, D. Y. et al. Relation of cardiac dysfunction to rhythm abnormalities in patients with Duchenne or Becker muscular dystrophies. Am. J. Cardiol. 117, 1349\u20131354 (2016).","journal-title":"Am. J. Cardiol."},{"key":"775_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.nmd.2010.09.006","volume":"21","author":"Y Ishikawa","year":"2011","unstructured":"Ishikawa, Y. et al. Duchenne muscular dystrophy: survival by cardio-respiratory interventions. Neuromuscul. Disord. 21, 47\u201351 (2011).","journal-title":"Neuromuscul. Disord."},{"key":"775_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-021-00255-4","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S., Mercuri,E. & Aartsma-Rus, A. Duchenne muscular dystrophy Nat. Rev. Dis. Prim. 7, 14 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"775_CR6","doi-asserted-by":"publisher","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","volume":"90","author":"BJ Petrof","year":"1993","unstructured":"Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M. & Sweeney, H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90, 3710\u20133714 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","volume":"84","author":"V Ricotti","year":"2013","unstructured":"Ricotti, V. et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J. Neurol. Neurosurg. Psychiatry 84, 698\u2013705 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"775_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant, D. J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 17, 347\u2013361 (2018).","journal-title":"Lancet Neurol."},{"key":"775_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01758-9","volume":"16","author":"S Kourakis","year":"2021","unstructured":"Kourakis, S. et al. Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better? Orphanet J. Rare Dis. 16, 117 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"775_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/165019701750300609","volume":"33","author":"P Vestergaard","year":"2001","unstructured":"Vestergaard, P. et al. Fracture risk in patients with muscular dystrophy and spinal muscular atrophy. J. Rehabil. Med. 33, 150\u2013155 (2001).","journal-title":"J. Rehabil. Med."},{"key":"775_CR11","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000008168","volume":"93","author":"EP Hoffman","year":"2019","unstructured":"Hoffman, E. P. et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology 93, e1312\u2013e1323 (2019).","journal-title":"Neurology"},{"key":"775_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/0092-8674(91)90035-W","volume":"66","author":"JM Ervasti","year":"1991","unstructured":"Ervasti, J. M. & Campbell, K. P. Membrane organization of the dystrophin-glycoprotein complex. Cell 66, 1121\u20131131 (1991).","journal-title":"Cell"},{"key":"775_CR13","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1083\/jcb.150.5.1209","volume":"150","author":"IN Rybakova","year":"2000","unstructured":"Rybakova, I. N., Patel, J. R. & Ervasti, J. M. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 150, 1209\u20131214 (2000).","journal-title":"J. Cell Biol."},{"key":"775_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/sj.embor.7400140","volume":"5","author":"HJ Spence","year":"2004","unstructured":"Spence, H. J., Dhillon, A. S., James, M. & Winder, S. J. Dystroglycan, a scaffold for the ERK-MAP kinase cascade. EMBO Rep. 5, 484\u2013489 (2004).","journal-title":"EMBO Rep."},{"key":"775_CR15","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1038\/nm.3990","volume":"21","author":"NA Dumont","year":"2015","unstructured":"Dumont, N. A. et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat. Med. 21, 1455\u20131463 (2015).","journal-title":"Nat. Med."},{"key":"775_CR16","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1093\/hmg\/ddv381","volume":"24","author":"TC Roberts","year":"2015","unstructured":"Roberts, T. C. et al. Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum. Mol. Genet. 24, 6756\u20136768 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1074\/mcp.RA120.002345","volume":"19","author":"TLE van Westering","year":"2020","unstructured":"van Westering, T. L. E. et al. Mutation-independent proteomic signatures of pathological progression in murine models of duchenne muscular dystrophy. Mol. Cell Proteom. 19, 2047\u20132067 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"775_CR18","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1017\/S1462399409001203","volume":"11","author":"D Sandon\u00e0","year":"2009","unstructured":"Sandon\u00e0, D. & Betto, R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert. Rev. Mol. Med. 11, e28 (2009).","journal-title":"Expert. Rev. Mol. Med."},{"key":"775_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2119\/molmed.2011.00049","volume":"17","author":"S Consalvi","year":"2011","unstructured":"Consalvi, S. et al. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol. Med. 17, 457\u2013465 (2011).","journal-title":"Mol. Med."},{"key":"775_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.scr.2014.10.007","volume":"14","author":"L Boldrin","year":"2015","unstructured":"Boldrin, L., Zammit, P. S. & Morgan, J. E. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Res. 14, 20\u201329 (2015).","journal-title":"Stem Cell Res."},{"key":"775_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-015-0036-8","volume":"5","author":"J Meng","year":"2015","unstructured":"Meng, J., Bencze, M., Asfahani, R., Muntoni, F. & Morgan, J. E. The effect of the muscle environment on the regenerative capacity of human skeletal muscle stem cells. Skelet. Muscle 5, 11 (2015).","journal-title":"Skelet. Muscle"},{"key":"775_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/ng.2974","volume":"46","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat. Genet. 46, 601\u2013606 (2014).","journal-title":"Nat. Genet."},{"key":"775_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07578-z","volume":"9","author":"GL Gallia","year":"2018","unstructured":"Gallia, G. L. et al. Genomic analysis identifies frequent deletions of dystrophin in olfactory neuroblastoma. Nat. Commun. 9, 5410 (2018).","journal-title":"Nat. Commun."},{"key":"775_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen, C. L. et al. The TREAT-NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"775_CR25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/humu.20367","volume":"27","author":"SJ White","year":"2006","unstructured":"White, S. J. et al. Duplications in the DMD gene. Hum. Mutat. 27, 938\u2013945 (2006).","journal-title":"Hum. Mutat."},{"key":"775_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura, A. et al. Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J. Hum. Genet. 61, 663\u2013667 (2016).","journal-title":"J. Hum. Genet."},{"key":"775_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2017","unstructured":"Nakamura, A. et al. Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J. Hum. Genet. 62, 459\u2013463 (2017).","journal-title":"J. Hum. Genet."},{"key":"775_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731\u2013740 (2003).","journal-title":"Lancet Neurol."},{"key":"775_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","volume":"343","author":"SB England","year":"1990","unstructured":"England, S. B. et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343, 180\u2013182 (1990).","journal-title":"Nature"},{"key":"775_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1172\/JCI116989","volume":"93","author":"K Matsumura","year":"1994","unstructured":"Matsumura, K. et al. Immunohistochemical analysis of dystrophin-associated proteins in Becker\/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. J. Clin. Invest. 93, 99\u2013105 (1994).","journal-title":"J. Clin. Invest."},{"key":"775_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. & Kunkel, L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90\u201395 (1988).","journal-title":"Genomics"},{"key":"775_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/jpm11010046","volume":"11","author":"S Anwar","year":"2021","unstructured":"Anwar, S., He, M., Lim, K. R. Q., Maruyama, R. & Yokota, T. A genotype-phenotype correlation study of exon skip-equivalent in-frame deletions and exon skip-amenable out-of-frame deletions across the DMD gene to simulate the effects of exon-skipping therapies: a meta-analysis. J. Pers. Med. 11, 46 (2021).","journal-title":"J. Pers. Med."},{"key":"775_CR33","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig, M. et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am. J. Hum. Genet. 45, 498\u2013506 (1989).","journal-title":"Am. J. Hum. Genet."},{"key":"775_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1126\/science.3055295","volume":"242","author":"S Malhotra","year":"1988","unstructured":"Malhotra, S. et al. Frame-shift deletions in patients with Duchenne and Becker muscular dystrophy. Science 242, 755\u2013759 (1988).","journal-title":"Science"},{"key":"775_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02346-1","volume":"17","author":"G Del Rio-Pertuz","year":"2022","unstructured":"Del Rio-Pertuz, G., Morataya, C., Parmar, K., Dubay, S. & Argueta-Sosa, E. Dilated cardiomyopathy as the initial presentation of Becker muscular dystrophy: a systematic review of published cases. Orphanet J. Rare Dis. 17, 194 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"775_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus, A. et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293\u2013299 (2009).","journal-title":"Hum. Mutat."},{"key":"775_CR37","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","volume":"76","author":"YY Syed","year":"2016","unstructured":"Syed, Y. Y. Eteplirsen: first global approval. Drugs 76, 1699\u20131704 (2016).","journal-title":"Drugs"},{"key":"775_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","volume":"80","author":"Y-A Heo","year":"2020","unstructured":"Heo, Y.-A. Golodirsen: first approval. Drugs 80, 329\u2013333 (2020).","journal-title":"Drugs"},{"key":"775_CR39","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley, M. Casimersen: first approval. Drugs 81, 875\u2013879 (2021).","journal-title":"Drugs"},{"key":"775_CR40","doi-asserted-by":"publisher","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","volume":"10","author":"H Komaki","year":"2018","unstructured":"Komaki, H. et al. Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. Sci. Transl. Med. 10, eaan0713 (2018).","journal-title":"Sci. Transl. Med."},{"key":"775_CR41","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens, P. R. et al. Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 77, 982\u2013991 (2020).","journal-title":"JAMA Neurol."},{"key":"775_CR42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Viltolarsen: first approval. Drugs 80, 1027\u20131031 (2020).","journal-title":"Drugs"},{"key":"775_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/nat.2018.0756","volume":"29","author":"A Aartsma-Rus","year":"2018","unstructured":"Aartsma-Rus, A. & Goemans, N. A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe. Nucleic Acid. Ther. 29, 13\u201315 (2018).","journal-title":"Nucleic Acid. Ther."},{"key":"775_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nbt.3819","volume":"35","author":"F Muntoni","year":"2017","unstructured":"Muntoni, F., Fletcher, S. & Wilton, S. Response to \u201cRailroading at the FDA\u201d. Nat. Biotechnol. 35, 207\u2013209 (2017).","journal-title":"Nat. Biotechnol."},{"key":"775_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus, A. & Krieg, A. M. FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga. Nucleic Acid. Ther. 27, 1\u20133 (2017).","journal-title":"Nucleic Acid. Ther."},{"key":"775_CR46","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","volume":"12","author":"JJ Dowling","year":"2016","unstructured":"Dowling, J. J. Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line. Nat. Rev. Neurol. 12, 675\u2013676 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"775_CR47","unstructured":"FDA Briefing Document, Peripheral and Central Nervous System Drugs Advisory Committee Meeting, 22 January 2016, NDA 206488, Eteplirsen (FDA, 2016); https:\/\/www.fda.gov\/files\/advisory%20committees\/published\/FDA-Briefing-Information-for-the-January-22-2016-Meeting-of-the-Peripheral-and-Central-Nervous-System-Drugs-Advisory-Committee.pdf."},{"key":"775_CR48","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/nbt.3733","volume":"34","author":"No authors listed.","year":"2016","unstructured":"No authors listed. Railroading at the FDA. Nat. Biotechnol. 34, 1078\u20131078 (2016).","journal-title":"Nat. Biotechnol."},{"key":"775_CR49","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 90, e2146\u2013e2154 (2018).","journal-title":"Neurology"},{"key":"775_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais, L. et al. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid. Ther. 32, 29\u201339 (2022).","journal-title":"Nucleic Acid. Ther."},{"key":"775_CR51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637\u2013647 (2013).","journal-title":"Ann. Neurol."},{"key":"775_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257\u2013271 (2016).","journal-title":"Ann. Neurol."},{"key":"775_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/gt.2009.120","volume":"17","author":"B Wu","year":"2010","unstructured":"Wu, B. et al. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther. 17, 132\u2013140 (2010).","journal-title":"Gene Ther."},{"key":"775_CR54","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JND-200548","volume":"8","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J. Neuromuscul. Dis. 8, 469\u2013479 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"775_CR55","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts, T. C., Langer, R. Wood, M. J. A. Advances in oligonucleotide drug delivery Nat. Rev. Drug Discov. 19, 673\u2013694 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"775_CR56","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/mtna.2012.30","volume":"1","author":"C Betts","year":"2012","unstructured":"Betts, C. et al. Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids 1, e38 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"775_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/srep08986","volume":"5","author":"CA Betts","year":"2015","unstructured":"Betts, C. A. et al. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci. Rep. 5, 8986 (2015).","journal-title":"Sci. Rep."},{"key":"775_CR58","unstructured":"Sarepta therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with duchenne muscular dystrophy amenable to skipping exon 51. Sarepta Therapeutics (5 May 2021); https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-reports-positive-clinical-results-phase-2."},{"key":"775_CR59","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","volume":"1798","author":"HM Moulton","year":"2010","unstructured":"Moulton, H. M. & Moulton, J. D. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 1798, 2296\u20132303 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"775_CR60","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","volume":"18","author":"A Amantana","year":"2007","unstructured":"Amantana, A. et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug. Chem. 18, 1325\u20131331 (2007).","journal-title":"Bioconjug. Chem."},{"key":"775_CR61","unstructured":"PepGen reports positive data from phase 1 trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy. PepGen (28 September 2022); https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-reports-positive-data-phase-1-trial-pgn-edo51-treatment\/."},{"key":"775_CR62","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.nmd.2022.07.349","volume":"32","author":"N Kreher","year":"2022","unstructured":"Kreher, N. et al. P.194 Development of a novel, EEV-conjugated PMO for Duchenne muscular dystrophy. Neuromuscul. Disord. 32, S126 (2022).","journal-title":"Neuromuscul. Disord."},{"key":"775_CR63","unstructured":"Avidity Biosciences Announces Phase 1\/2 EXPLORE44TM Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping (Avidity Biosciences, 2022); https:\/\/aviditybiosciences.investorroom.com\/2022-10-11-Avidity-Biosciences-Announces-Phase-1-2-EXPLORE44-TM-Trial-of-AOC-1044-for-Duchenne-Muscular-Dystrophy-Mutations-Amenable-to-Exon-44-Skipping."},{"key":"775_CR64","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.1093\/nar\/gkac641","volume":"50","author":"CA Desjardins","year":"2022","unstructured":"Desjardins, C. A. et al. Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice. Nucleic Acids Res. 50, 11401\u201311414 (2022).","journal-title":"Nucleic Acids Res."},{"key":"775_CR65","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki, Y. et al. Bodywide skipping of exons 45\u201355 in dystrophic mdx52 mice by systemic antisense delivery. Proc. Natl Acad. Sci. USA 109, 13763\u201313768 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR66","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"C B\u00e9roud","year":"2007","unstructured":"B\u00e9roud, C. et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum. Mutat. 28, 196\u2013202 (2007).","journal-title":"Hum. Mutat."},{"key":"775_CR67","unstructured":"Wave Life Sciences provides positive update on proof-of-concept study for WVE-N531 in Duchenne muscular dystrophy. GlobeNewswire News Room (WAVE Life Science USA, 2022); https:\/\/www.globenewswire.com\/news-release\/2022\/12\/19\/2576214\/0\/en\/Wave-Life-Sciences-Provides-Positive-Update-on-Proof-of-Concept-Study-for-WVE-N531-in-Duchenne-Muscular-Dystrophy.html."},{"key":"775_CR68","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1093\/nar\/gkac018","volume":"50","author":"P Kandasamy","year":"2022","unstructured":"Kandasamy, P. et al. Control of backbone chemistry and chirality boost oligonucleotide splice switching activity. Nucleic Acids Res. 50, 5443\u20135466 (2022).","journal-title":"Nucleic Acids Res."},{"key":"775_CR69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto, N. et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat. Biotechnol. 35, 845\u2013851 (2017).","journal-title":"Nat. Biotechnol."},{"key":"775_CR70","doi-asserted-by":"publisher","first-page":"13456","DOI":"10.1093\/nar\/gku1115","volume":"42","author":"WB Wan","year":"2014","unstructured":"Wan, W. B. et al. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. Nucleic Acids Res. 42, 13456\u201313468 (2014).","journal-title":"Nucleic Acids Res."},{"key":"775_CR71","unstructured":"Wave Life Sciences provides update on phase 1b\/2a PRECISION-HD trials - Wave Life Sciences. Wave Life Sciences (2021); https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-provides-update-phase-1b2a-precision-hd."},{"key":"775_CR72","unstructured":"Wave Life Sciences announces discontinuation of suvodirsen development for Duchenne muscular dystrophy. Wave Life Sciences (16 December 2019); https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-discontinuation-suvodirsen."},{"key":"775_CR73","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cimb43030090","volume":"43","author":"K Ito","year":"2021","unstructured":"Ito, K. et al. Renadirsen, a novel 2\u2019OMeRNA\/ENA\u00ae chimera antisense oligonucleotide, induces robust exon 45 skipping for dystrophin in vivo. Curr. Issues Mol. Biol. 43, 1267\u20131281 (2021).","journal-title":"Curr. Issues Mol. Biol."},{"key":"775_CR74","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nm.3765","volume":"21","author":"A Goyenvalle","year":"2015","unstructured":"Goyenvalle, A. et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med. 21, 270\u2013275 (2015).","journal-title":"Nat. Med."},{"key":"775_CR75","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ana.26409","volume":"92","author":"F Zarrouki","year":"2022","unstructured":"Zarrouki, F. et al. Partial restoration of brain dystrophin and behavioral deficits by exon skipping in the muscular dystrophy X-linked (mdx) mouse. Ann. Neurol. 92, 213\u2013229 (2022).","journal-title":"Ann. Neurol."},{"key":"775_CR76","doi-asserted-by":"publisher","first-page":"9456","DOI":"10.1073\/pnas.142302299","volume":"99","author":"FG De Angelis","year":"2002","unstructured":"De Angelis, F. G. et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc. Natl Acad. Sci. USA 99, 9456\u20139461 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR77","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1126\/science.1104297","volume":"306","author":"A Goyenvalle","year":"2004","unstructured":"Goyenvalle, A. et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306, 1796\u20131799 (2004).","journal-title":"Science"},{"key":"775_CR78","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.omtm.2021.03.014","volume":"21","author":"TR Simmons","year":"2021","unstructured":"Simmons, T. R. et al. Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping. Mol. Ther. Methods Clin. Dev. 21, 325\u2013340 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"775_CR79","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/nm.3628","volume":"20","author":"N Wein","year":"2014","unstructured":"Wein, N. et al. Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nat. Med. 20, 992\u20131000 (2014).","journal-title":"Nat. Med."},{"key":"775_CR80","unstructured":"Nationwide Children\u2019s Hospital Announces Restoration of Full-Length Dystrophin Using dup 2 Gene Therapy Approach (Parent Project Muscular Dystrophy, 2022); https:\/\/www.parentprojectmd.org\/nationwide-childrens-hospital-announces-restoration-of-full-length-dystrophin-using-duplication-2-gene-therapy-approach\/."},{"key":"775_CR81","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1172\/JCI7866","volume":"104","author":"ER Barton-Davis","year":"1999","unstructured":"Barton-Davis, E. R., Cordier, L., Shoturma, D. I., Leland, S. E. & Sweeney, H. L. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104, 375\u2013381 (1999).","journal-title":"J. Clin. Invest."},{"key":"775_CR82","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ana.1023","volume":"49","author":"KR Wagner","year":"2001","unstructured":"Wagner, K. R. et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706\u2013711 (2001).","journal-title":"Ann. Neurol."},{"key":"775_CR83","first-page":"15","volume":"22","author":"L Politano","year":"2003","unstructured":"Politano, L. et al. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22, 15\u201321 (2003).","journal-title":"Acta Myol."},{"key":"775_CR84","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.22024","volume":"67","author":"V Malik","year":"2010","unstructured":"Malik, V. et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 67, 771\u2013780 (2010).","journal-title":"Ann. Neurol."},{"key":"775_CR85","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/bcp.13439","volume":"84","author":"RS Hayward","year":"2018","unstructured":"Hayward, R. S. et al. Adverse effects of a single dose of gentamicin in adults: a systematic review. Br. J. Clin. Pharmacol. 84, 223\u2013238 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"775_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch, E. M. et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87\u201391 (2007).","journal-title":"Nature"},{"key":"775_CR87","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","volume":"74","author":"NJ Ryan","year":"2014","unstructured":"Ryan, N. J. Ataluren: first global approval. Drugs 74, 1709\u20131714 (2014).","journal-title":"Drugs"},{"key":"775_CR88","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby, K. et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50, 477\u2013487 (2014).","journal-title":"Muscle Nerve"},{"key":"775_CR89","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald, C. M. et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1489\u20131498 (2017).","journal-title":"Lancet"},{"key":"775_CR90","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt1117-999","volume":"35","author":"No authors listed.","year":"2017","unstructured":"No authors listed.Duchenne drug clings on for FDA nodNat. Biotechnol. 35, 999 (2017).","journal-title":"Nat. Biotechnol."},{"key":"775_CR91","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2217\/cer-2020-0095","volume":"9","author":"C Campbell","year":"2020","unstructured":"Campbell, C. et al. Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. J. Comp. Eff. Res. 9, 973\u2013984 (2020).","journal-title":"J. Comp. Eff. Res."},{"key":"775_CR92","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1073\/pnas.0909141107","volume":"107","author":"DS Auld","year":"2010","unstructured":"Auld, D. S. et al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc. Natl Acad. Sci. USA 107, 4878\u20134883 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR93","doi-asserted-by":"publisher","first-page":"e1001593","DOI":"10.1371\/journal.pbio.1001593","volume":"11","author":"SP McElroy","year":"2013","unstructured":"McElroy, S. P. et al. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol. 11, e1001593 (2013).","journal-title":"PLoS Biol."},{"key":"775_CR94","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1128\/JVI.74.3.1524-1532.2000","volume":"74","author":"CL Halbert","year":"2000","unstructured":"Halbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W. & Miller, A. D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524\u20131532 (2000).","journal-title":"J. Virol."},{"key":"775_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/9780471729259.mc14d03s28","author":"AM Gruntman","year":"2013","unstructured":"Gruntman, A. M. et al. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr. Protoc. Microbiol. https:\/\/doi.org\/10.1002\/9780471729259.mc14d03s28 (2013).","journal-title":"Curr. Protoc. Microbiol."},{"key":"775_CR96","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-61779-370-7_5","volume":"807","author":"C Qiao","year":"2011","unstructured":"Qiao, C., Koo, T., Li, J., Xiao, X. & Dickson, J. G. Gene therapy in skeletal muscle mediated by adeno-associated virus vectors. Methods Mol. Biol. 807, 119\u2013140 (2011).","journal-title":"Methods Mol. Biol."},{"key":"775_CR97","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic, P. et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828\u2013834 (2004).","journal-title":"Nat. Med."},{"key":"775_CR98","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan, D. Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol. Ther. 26, 2337\u20132356 (2018).","journal-title":"Mol. Ther."},{"key":"775_CR99","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41434-022-00317-6","volume":"29","author":"A Bourdon","year":"2022","unstructured":"Bourdon, A. et al. Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMDmdx rat model. Gene Ther. 29, 520\u2013535 (2022).","journal-title":"Gene Ther."},{"key":"775_CR100","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/364725a0","volume":"364","author":"GA Cox","year":"1993","unstructured":"Cox, G. A. et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 364, 725\u2013729 (1993).","journal-title":"Nature"},{"key":"775_CR101","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1089\/hum.2019.255","volume":"32","author":"RA Potter","year":"2021","unstructured":"Potter, R. A. et al. Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of duchenne muscular dystrophy. Hum. Gene Ther. 32, 375\u2013389 (2021).","journal-title":"Hum. Gene Ther."},{"key":"775_CR102","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1093\/hmg\/ddv310","volume":"24","author":"Y Yue","year":"2015","unstructured":"Yue, Y. et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum. Mol. Genet. 24, 5880\u20135890 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner, C. et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat. Commun. 8, 16105 (2017).","journal-title":"Nat. Commun."},{"key":"775_CR104","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva, M. Z. et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15, 320\u2013329 (2007).","journal-title":"Mol. Ther."},{"key":"775_CR105","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/mt.2013.246","volume":"22","author":"LG Chicoine","year":"2014","unstructured":"Chicoine, L. G. et al. Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates. Mol. Ther. 22, 713\u2013724 (2014).","journal-title":"Mol. Ther."},{"key":"775_CR106","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1089\/hum.2016.141","volume":"28","author":"DA Zygmunt","year":"2017","unstructured":"Zygmunt, D. A., Crowe, K. E., Flanigan, K. M. & Martin, P. T. Comparison of serum rAAV serotype-specific antibodies in patients with duchenne muscular dystrophy, becker muscular dystrophy, inclusion body myositis, or GNE myopathy. Hum. Gene Ther. 28, 737\u2013746 (2017).","journal-title":"Hum. Gene Ther."},{"key":"775_CR107","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell, J. R. et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 77, 1122\u20131131 (2020).","journal-title":"JAMA Neurol."},{"key":"775_CR108","doi-asserted-by":"publisher","first-page":"e2031851","DOI":"10.1001\/jamanetworkopen.2020.31851","volume":"4","author":"RJ Willcocks","year":"2021","unstructured":"Willcocks, R. J. et al. Assessment of rAAVrh.74.MHCK7.micro-dystrophin gene therapy using magnetic resonance imaging in children with duchenne muscular dystrophy. JAMA Netw. Open 4, e2031851 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"Suppl. 15","key":"775_CR109","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1212\/WNL.96.15_supplement.4478","volume":"96","author":"J Mendell","year":"2021","unstructured":"Mendell, J. et al. A multicenter randomized, double-blind, placebo-controlled, gene-delivery clinical trial of rAAVrh74.MHCK7.micro-dystrophin for Duchenne muscular dystrophy [Abstr.]. Neurology 96 (Suppl. 15), 4478 (2021).","journal-title":"Neurology"},{"key":"775_CR110","unstructured":"Sarepta Therapeutics announces top-line results for part 1 of study 102 evaluating SRP-9001, its investigational gene therapy for the treatment of Duchenne muscular dystrophy. Sarepta Therapeutics (7 Junuary 2021); https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-top-line-results-part-1-study-102."},{"key":"775_CR111","unstructured":"Sarepta Therapeutics\u2019 investigational gene therapy SRP-9001 for Duchenne muscular dystrophy demonstrates significant functional improvements across multiple studies. Sarepta Therapeutics (6 July 2022); https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-investigational-gene-therapy-srp-9001."},{"key":"775_CR112","unstructured":"Sarepta Therapeutics announces that U.S. FDA has accepted for filing and granted priority review for the Biologics License Application for SRP-9001, Sarepta\u2019s gene therapy for the treatment of ambulant individuals with Duchenne muscular dystrophy. Sarepta Therapeutics (28 November 2022); https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-us-fda-has-accepted-filing-and."},{"key":"775_CR113","unstructured":"Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne muscular dystrophy. Sarepta Therapeutics (22 June 2023); https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene."},{"key":"775_CR114","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis, A. After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Hum. Gene Ther. 33, 111\u2013115 (2022).","journal-title":"Hum. Gene Ther."},{"key":"775_CR115","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/hum.2022.29203.bfs","volume":"33","author":"A Philippidis","year":"2022","unstructured":"Philippidis, A. Pfizer eyes resuming phase III enrollment, investigates phase Ib death tied to Duchenne muscular dystrophy candidate. Hum. Gene Ther. 33, 215\u2013217 (2022).","journal-title":"Hum. Gene Ther."},{"key":"775_CR116","unstructured":"Pfizer\u2019s new phase 1b results of gene therapy in ambulatory boys with Duchenne muscular dystrophy (DMD) support advancement into pivotal phase 3 study. Pfizer (15 May 2020); https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys."},{"key":"775_CR117","unstructured":"Philippidis, A. FDA lifts clinical hold on Pfizer DMD gene therapy linked to patient death. GEN - Genetic Engineering and Biotechnology News (28 April 2022); https:\/\/www.genengnews.com\/topics\/genome-editing\/gene-therapy\/fda-lifts-clinical-hold-on-pfizer-dmd-gene-therapy-linked-to-patient-death\/."},{"key":"775_CR118","unstructured":"Pfizer announces amendment to ongoing gene therapy phase III trial. Parent Project Muscular Dystrophy (28 September 2021); https:\/\/www.parentprojectmd.org\/pfizer-announces-amendment-to-ongoing-gene-therapy-phase-iii-trial\/."},{"key":"775_CR119","unstructured":"Collaborative analysis reveals \u2018class effect\u2019 in DMD safety issues. BioSpace (19 May 2022); https:\/\/www.biospace.com\/article\/pfizer-sarepta-genethon-solid-bio-team-up-to-fight-dmd\/."},{"key":"775_CR120","unstructured":"Solid Biosciences provides SGT-001 program update. Solid Biosciences (19 November 2019); https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-provides-sgt-001-program-update."},{"key":"775_CR121","unstructured":"Solid Biosciences announces FDA lifts clinical hold on IGNITE DMD clinical trial. Solid Biosciences (1 October 2020); https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-announces-fda-lifts-clinical-hold-on-ignite-dmd-clinical-trial."},{"key":"775_CR122","doi-asserted-by":"crossref","unstructured":"Solid Biosciences reports fourth quarter and full-year 2021 financial results and 2-year efficacy and safety data from the ongoing phase I\/II IGNITE DMD clinical trial of SGT-001. Solid Biosciences (14 March 2022); https:\/\/www.solidbio.com\/about\/media\/press-releases\/solid-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-2-year-efficacy-and-safety-data-from-the-ongoing-phase-i-ii-ignite-dmd-clinical-trial-of-sgt-001.","DOI":"10.1016\/j.fopow.2021.03.008"},{"key":"775_CR123","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41587-020-0642-9","volume":"38","author":"No authors listed.","year":"2020","unstructured":"High-dose AAV gene therapy deaths. Nat. Biotechnol. 38, 910 (2020).","journal-title":"Nat. Biotechnol."},{"key":"775_CR124","unstructured":"Lysogene confirms child\u2019s death in phase II\/III gene therapy trial. GEN (26 October 2020); https:\/\/www.genengnews.com\/news\/lysogene-confirms-childs-death-in-phase-ii-iii-gene-therapy-trial\/."},{"key":"775_CR125","unstructured":"Reuters. Novartis reports Zolgensma caused two deaths from liver failure. Reuters (11 August 2022); https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/novartis-reports-zolgensma-caused-two-deaths-liver-failure-2022-08-11\/."},{"key":"775_CR126","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285\u2013298 (2018).","journal-title":"Hum. Gene Ther."},{"key":"775_CR127","unstructured":"Hale, C. Solid Bio Sees Yet Another Clinical Hold for its DMD Gene Therapy (Fierce Biotech, 2019); https:\/\/www.fiercebiotech.com\/biotech\/solid-bio-sees-yet-another-clinical-hold-for-its-dmd-gene-therapy."},{"key":"775_CR128","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"VL Jeune","year":"2013","unstructured":"Jeune, V. L., Joergensen, J. A., Hajjar, R. J. & Weber, T. Pre-existing anti\u2013adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59\u201367 (2013).","journal-title":"Hum. Gene Ther. Methods"},{"key":"775_CR129","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010).","journal-title":"N. Engl. J. Med."},{"key":"775_CR130","doi-asserted-by":"publisher","first-page":"S325","DOI":"10.3233\/JND-210706","volume":"8","author":"N Li","year":"2021","unstructured":"Li, N. et al. The effect of immunomodulatory treatments on anti-Dystrophin immune response after AAV gene therapy in dystrophin deficient mdx mice. J. Neuromuscul. Dis. 8, S325\u2013S340 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"775_CR131","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1182\/blood-2004-06-2501","volume":"105","author":"VM Rivera","year":"2005","unstructured":"Rivera, V. M. et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105, 1424\u20131430 (2005).","journal-title":"Blood"},{"key":"775_CR132","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1128\/JVI.00649-08","volume":"82","author":"M Penaud-Budloo","year":"2008","unstructured":"Penaud-Budloo, M. et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J. Virol. 82, 7875\u20137885 (2008).","journal-title":"J. Virol."},{"key":"775_CR133","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/mt.2013.121","volume":"21","author":"M Le Hir","year":"2013","unstructured":"Le Hir, M. et al. AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy. Mol. Ther. 21, 1551\u20131558 (2013).","journal-title":"Mol. Ther."},{"key":"775_CR134","doi-asserted-by":"publisher","first-page":"e0203921","DOI":"10.1128\/jvi.02039-21","volume":"96","author":"A Das","year":"2022","unstructured":"Das, A. et al. Epigenetic silencing of recombinant adeno-associated virus genomes by NP220 and the HUSH complex. J. Virol. 96, e0203921 (2022).","journal-title":"J. Virol."},{"key":"775_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13405-9","volume":"12","author":"A Mollard","year":"2022","unstructured":"Mollard, A. et al. Muscle regeneration affects adeno associated virus 1 mediated transgene transcription. Sci. Rep. 12, 9674 (2022).","journal-title":"Sci. Rep."},{"key":"775_CR136","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1083\/jcb.111.6.2437","volume":"111","author":"JE Morgan","year":"1990","unstructured":"Morgan, J. E., Hoffman, E. P. & Partridge, T. A. Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J. Cell Biol. 111, 2437\u20132449 (1990).","journal-title":"J. Cell Biol."},{"key":"775_CR137","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/337176a0","volume":"337","author":"TA Partridge","year":"1989","unstructured":"Partridge, T. A., Morgan, J. E., Coulton, G. R., Hoffman, E. P. & Kunkel, L. M. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337, 176\u2013179 (1989).","journal-title":"Nature"},{"key":"775_CR138","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.stemcr.2018.01.022","volume":"10","author":"SM Garcia","year":"2018","unstructured":"Garcia, S. M. et al. High-yield purification, preservation, and serial transplantation of human satellite cells. Stem Cell Rep. 10, 1160\u20131174 (2018).","journal-title":"Stem Cell Rep."},{"key":"775_CR139","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1126\/science.279.5356.1528","volume":"279","author":"G Ferrari","year":"1998","unstructured":"Ferrari, G. et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279, 1528\u20131530 (1998).","journal-title":"Science"},{"key":"775_CR140","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/43919","volume":"401","author":"E Gussoni","year":"1999","unstructured":"Gussoni, E. et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 401, 390\u2013394 (1999).","journal-title":"Nature"},{"key":"775_CR141","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.15252\/emmm.201505636","volume":"7","author":"G Cossu","year":"2015","unstructured":"Cossu, G. et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol. Med. 7, 1513\u20131528 (2015).","journal-title":"EMBO Mol. Med."},{"key":"775_CR142","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ncb1542","volume":"9","author":"A Dellavalle","year":"2007","unstructured":"Dellavalle, A. et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9, 255\u2013267 (2007).","journal-title":"Nat. Cell Biol."},{"key":"775_CR143","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3727\/000000007783465064","volume":"16","author":"Y Torrente","year":"2007","unstructured":"Torrente, Y. et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transpl. 16, 563\u2013577 (2007).","journal-title":"Cell Transpl."},{"key":"775_CR144","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","volume":"18","author":"CS Young","year":"2016","unstructured":"Young, C. S. et al. A single CRISPR-Cas9 deletion strategy that targets the majority of DMD patients restores dystrophin function in hiPSC-derived muscle cells. Cell Stem Cell 18, 533\u2013540 (2016).","journal-title":"Cell Stem Cell"},{"key":"775_CR145","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/01.jnen.0000218443.45782.81","volume":"65","author":"D Skuk","year":"2006","unstructured":"Skuk, D. et al. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J. Neuropathol. Exp. Neurol. 65, 371\u2013386 (2006).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"775_CR146","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/cells8091066","volume":"8","author":"N Motohashi","year":"2019","unstructured":"Motohashi, N., Shimizu-Motohashi, Y., Roberts, T. C. & Aoki, Y. Potential therapies using myogenic stem cells combined with bio-engineering approaches for treatment of muscular dystrophies. Cells 8, 1066 (2019).","journal-title":"Cells"},{"key":"775_CR147","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1023\/A:1025425823322","volume":"24","author":"D Skuk","year":"2003","unstructured":"Skuk, D. & Tremblay, J. P. Myoblast transplantation: the current status of a potential therapeutic tool for myopathies. J. Muscle Res. Cell Motil. 24, 285\u2013300 (2003).","journal-title":"J. Muscle Res. Cell Motil."},{"key":"775_CR148","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","volume":"92","author":"M Taylor","year":"2019","unstructured":"Taylor, M. et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology 92, e866\u2013e878 (2019).","journal-title":"Neurology"},{"key":"775_CR149","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","volume":"399","author":"CM McDonald","year":"2022","unstructured":"McDonald, C. M. et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 399, 1049\u20131058 (2022).","journal-title":"Lancet"},{"key":"775_CR150","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","volume":"18","author":"B Hanson","year":"2021","unstructured":"Hanson, B., Wood, M. J. A. & Roberts, T. C. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. RNA Biol. 18, 1048\u20131062 (2021).","journal-title":"RNA Biol."},{"key":"775_CR151","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"775_CR152","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411 (2016).","journal-title":"Science"},{"key":"775_CR153","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407 (2016).","journal-title":"Science"},{"key":"775_CR154","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400\u2013403 (2016).","journal-title":"Science"},{"key":"775_CR155","doi-asserted-by":"publisher","first-page":"eaan8081","DOI":"10.1126\/scitranslmed.aan8081","volume":"9","author":"L Amoasii","year":"2017","unstructured":"Amoasii, L. et al. Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci. Transl. Med. 9, eaan8081 (2017).","journal-title":"Sci. Transl. Med."},{"key":"775_CR156","doi-asserted-by":"publisher","first-page":"14038","DOI":"10.1038\/mtm.2014.38","volume":"1","author":"AL Arnett","year":"2014","unstructured":"Arnett, A. L. et al. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol. Ther. Methods Clin. Dev. 1, 14038 (2014).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"775_CR157","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ymthe.2019.06.012","volume":"27","author":"ME Nance","year":"2019","unstructured":"Nance, M. E. et al. AAV9 edits muscle stem cells in normal and dystrophic adult mice. Mol. Ther. 27, 1568\u20131585 (2019).","journal-title":"Mol. Ther."},{"key":"775_CR158","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.omtm.2020.09.016","volume":"19","author":"JB Kwon","year":"2020","unstructured":"Kwon, J. B. et al. In vivo gene editing of muscle stem cells with adeno-associated viral vectors in a mouse model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 19, 320\u2013329 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"775_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7244","volume":"6","author":"DG Ousterout","year":"2015","unstructured":"Ousterout, D. G. et al. Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nat. Commun. 6, 6244 (2015).","journal-title":"Nat. Commun."},{"key":"775_CR160","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","volume":"171","author":"H-K Liao","year":"2017","unstructured":"Liao, H.-K. et al. In vivo target gene activation via CRISPR\/Cas9-mediated trans-epigenetic modulation. Cell 171, 1495\u20131507.e15 (2017).","journal-title":"Cell"},{"key":"775_CR161","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert, L. A. et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442\u2013451 (2013).","journal-title":"Cell"},{"key":"775_CR162","unstructured":"To Our Community: An Update On Our CRD-TMH-001 Clinical Trial (Cure Rare Disease, 2022); https:\/\/www.cureraredisease.org\/blog-posts\/to-our-community-an-update-on-our-crd-tmh-001-clinical-trial."},{"key":"775_CR163","doi-asserted-by":"publisher","unstructured":"Lek, A. et al. Unexpected death of a Duchenne muscular dystrophy patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator. Preprint at https:\/\/doi.org\/10.1101\/2023.05.16.23289881 (2023).","DOI":"10.1101\/2023.05.16.23289881"},{"key":"775_CR164","unstructured":"Pipeline and Progress (Cure Rare Disease, accessed 2023); https:\/\/www.cureraredisease.org\/our-approach\/pipeline-and-progress#section_1."},{"key":"775_CR165","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.omtn.2022.10.010","volume":"30","author":"B Hanson","year":"2022","unstructured":"Hanson, B. et al. Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin\/utrophin double-knockout mouse model of DMD. Mol. Ther. - Nucleic Acids 30, 379\u2013397 (2022).","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"775_CR166","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","volume":"10","author":"VL Simhadri","year":"2018","unstructured":"Simhadri, V. L. et al. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol. Ther. Methods Clin. Dev. 10, 105\u2013112 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"775_CR167","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249\u2013254 (2019).","journal-title":"Nat. Med."},{"key":"775_CR168","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner, D. L. et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat. Med. 25, 242\u2013248 (2019).","journal-title":"Nat. Med."},{"key":"775_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson, N. E. et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. Commun. 8, 14454 (2017).","journal-title":"Nat. Commun."},{"key":"775_CR170","doi-asserted-by":"publisher","first-page":"e1602814","DOI":"10.1126\/sciadv.1602814","volume":"3","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci. Adv. 3, e1602814 (2017).","journal-title":"Sci. Adv."},{"key":"775_CR171","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto, E. M., Komor, A. C., Slaymaker, I. M. & Yeo, G. W. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug. Discov. 19, 839\u2013859 (2020).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"775_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23996-y","volume":"12","author":"L Xu","year":"2021","unstructured":"Xu, L. et al. Efficient precise in vivo base editing in adult dystrophic mice. Nat. Commun. 12, 3719 (2021).","journal-title":"Nat. Commun."},{"key":"775_CR173","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1093\/nar\/gkt076","volume":"41","author":"GL Dianov","year":"2013","unstructured":"Dianov, G. L. & H\u00fcbscher, U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. 41, 3483\u20133490 (2013).","journal-title":"Nucleic Acids Res."},{"key":"775_CR174","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nbt.4148","volume":"36","author":"S-M Ryu","year":"2018","unstructured":"Ryu, S.-M. et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 36, 536\u2013539 (2018).","journal-title":"Nat. Biotechnol."},{"key":"775_CR175","doi-asserted-by":"publisher","first-page":"eabg4910","DOI":"10.1126\/sciadv.abg4910","volume":"7","author":"F Chemello","year":"2021","unstructured":"Chemello, F. et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci. Adv. 7, eabg4910 (2021).","journal-title":"Sci. Adv."},{"key":"775_CR176","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"775_CR177","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1750-3639.1996.tb00781.x","volume":"6","author":"DJ Blake","year":"1996","unstructured":"Blake, D. J., Tinsley, J. M. & Davies, K. E. Utrophin: a structural and functional comparison to dystrophin. Brain Pathol. 6, 37\u201347 (1996).","journal-title":"Brain Pathol."},{"key":"775_CR178","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/360591a0","volume":"360","author":"JM Tinsley","year":"1992","unstructured":"Tinsley, J. M. et al. Primary structure of dystrophin-related protein. Nature 360, 591\u2013593 (1992).","journal-title":"Nature"},{"key":"775_CR179","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/339055a0","volume":"339","author":"DR Love","year":"1989","unstructured":"Love, D. R. et al. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339, 55\u201358 (1989).","journal-title":"Nature"},{"key":"775_CR180","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","volume":"71","author":"K Anthony","year":"2014","unstructured":"Anthony, K. et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol. 71, 32\u201340 (2014).","journal-title":"JAMA Neurol."},{"key":"775_CR181","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/360588a0","volume":"360","author":"K Matsumura","year":"1992","unstructured":"Matsumura, K., Ervasti, J. M., Ohlendieck, K., Kahl, S. D. & Campbell, K. P. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 360, 588\u2013591 (1992).","journal-title":"Nature"},{"key":"775_CR182","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0092-8674(00)80532-2","volume":"90","author":"AE Deconinck","year":"1997","unstructured":"Deconinck, A. E. et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717\u2013727 (1997).","journal-title":"Cell"},{"key":"775_CR183","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0092-8674(00)80533-4","volume":"90","author":"RM Grady","year":"1997","unstructured":"Grady, R. M. et al. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729\u2013738 (1997).","journal-title":"Cell"},{"key":"775_CR184","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/4033","volume":"4","author":"J Tinsley","year":"1998","unstructured":"Tinsley, J. et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat. Med. 4, 1441\u20131444 (1998).","journal-title":"Nat. Med."},{"key":"775_CR185","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1093\/hmg\/11.26.3333","volume":"11","author":"S Squire","year":"2002","unstructured":"Squire, S. et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum. Mol. Genet. 11, 3333\u20133344 (2002).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR186","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0960-8966(01)00220-6","volume":"11","author":"R Fisher","year":"2001","unstructured":"Fisher, R. et al. Non-toxic ubiquitous over-expression of utrophin in the mdx mouse. Neuromuscul. Disord. 11, 713\u2013721 (2001).","journal-title":"Neuromuscul. Disord."},{"key":"775_CR187","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","volume":"25","author":"Y Song","year":"2019","unstructured":"Song, Y. et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat. Med. 25, 1505\u20131511 (2019).","journal-title":"Nat. Med."},{"key":"775_CR188","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/jm200135z","volume":"54","author":"DR Chancellor","year":"2011","unstructured":"Chancellor, D. R. et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J. Med. Chem. 54, 3241\u20133250 (2011).","journal-title":"J. Med. Chem."},{"key":"775_CR189","doi-asserted-by":"publisher","first-page":"e19189","DOI":"10.1371\/journal.pone.0019189","volume":"6","author":"JM Tinsley","year":"2011","unstructured":"Tinsley, J. M. et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE 6, e19189 (2011).","journal-title":"PLoS ONE"},{"key":"775_CR190","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/cpdd.642","volume":"8","author":"F Muntoni","year":"2019","unstructured":"Muntoni, F. et al. A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric Duchenne muscular dystrophy patients on a balanced diet. Clin. Pharmacol. Drug Dev. 8, 922\u2013933 (2019).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"775_CR191","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/anie.201912392","volume":"59","author":"IVL Wilkinson","year":"2020","unstructured":"Wilkinson, I. V. L. et al. Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid. Angew. Chem. Int. Ed. 59, 2420\u20132428 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"775_CR192","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","volume":"24","author":"S Guiraud","year":"2015","unstructured":"Guiraud, S. et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum. Mol. Genet. 24, 4212\u20134224 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR193","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/384349a0","volume":"384","author":"JM Tinsley","year":"1996","unstructured":"Tinsley, J. M. et al. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384, 349\u2013353 (1996).","journal-title":"Nature"},{"key":"775_CR194","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/nm1197-1216","volume":"3","author":"N Deconinck","year":"1997","unstructured":"Deconinck, N. et al. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat. Med. 3, 1216\u20131221 (1997).","journal-title":"Nat. Med."},{"key":"775_CR195","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/mt.2008.149","volume":"16","author":"GL Odom","year":"2008","unstructured":"Odom, G. L., Gregorevic, P., Allen, J. M., Finn, E. & Chamberlain, J. S. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice. Mol. Ther. 16, 1539\u20131545 (2008).","journal-title":"Mol. Ther."},{"key":"775_CR196","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","volume":"22","author":"K Sengupta","year":"2020","unstructured":"Sengupta, K. et al. Genome editing-mediated utrophin upregulation in Duchenne muscular dystrophy stem cells. Mol. Ther. Nucleic Acids 22, 500\u2013509 (2020).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"775_CR197","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbadis.2018.01.030","volume":"1864","author":"C Pisani","year":"2018","unstructured":"Pisani, C. et al. Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1172\u20131182 (2018).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"775_CR198","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1242\/jcs.064808","volume":"123","author":"D Li","year":"2010","unstructured":"Li, D. et al. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J. Cell Sci. 123, 2008\u20132013 (2010).","journal-title":"J. Cell Sci."},{"key":"775_CR199","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1073\/pnas.1323842111","volume":"111","author":"JJ Belanto","year":"2014","unstructured":"Belanto, J. J. et al. Microtubule binding distinguishes dystrophin from utrophin. Proc. Natl Acad. Sci. USA 111, 5723\u20135728 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR200","doi-asserted-by":"publisher","first-page":"735912","DOI":"10.3389\/fphar.2021.735912","volume":"12","author":"T Markati","year":"2021","unstructured":"Markati, T., De Waele, L., Schara-Schmidt, U. & Servais, L. Lessons learned from discontinued clinical developments in Duchenne muscular dystrophy. Front. Pharmacol. 12, 735912 (2021).","journal-title":"Front. Pharmacol."},{"key":"775_CR201","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati, T. et al. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 21, 814\u2013829 (2022).","journal-title":"Lancet Neurol."},{"key":"775_CR202","unstructured":"Italfarmaco Group Announces Positive Topline Data From Phase 3 Trial Showing Beneficial Effect Of Givinostat in Patients with Duchenne Muscular Dystrophy (Businesswire, 2022); https:\/\/www.businesswire.com\/news\/home\/20220625005001\/en\/Italfarmaco-Group-Announces-Positive-Topline-Data-from-Phase-3-Trial-Showing-Beneficial-Effect-of-Givinostat-in-Patients-with-Duchenne-Muscular-Dystrophy."},{"key":"775_CR203","doi-asserted-by":"publisher","first-page":"19183","DOI":"10.1073\/pnas.0805514105","volume":"105","author":"C Colussi","year":"2008","unstructured":"Colussi, C. et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl Acad. Sci. USA 105, 19183\u201319187 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR204","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica, P. et al. Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 26, 643\u2013649 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"775_CR205","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/0092-8674(88)90463-1","volume":"52","author":"C Webster","year":"1988","unstructured":"Webster, C., Silberstein, L., Hays, A. P. & Blau, H. M. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52, 503\u2013513 (1988).","journal-title":"Cell"},{"key":"775_CR206","doi-asserted-by":"publisher","first-page":"C834","DOI":"10.1152\/ajpcell.1993.265.3.C834","volume":"265","author":"BJ Petrof","year":"1993","unstructured":"Petrof, B. J. et al. Adaptations in myosin heavy chain expression and contractile function in dystrophic mouse diaphragm. Am. J. Physiol. 265, C834\u2013C841 (1993).","journal-title":"Am. J. Physiol."},{"key":"775_CR207","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.nmd.2007.02.008","volume":"17","author":"A Oldfors","year":"2007","unstructured":"Oldfors, A. Hereditary myosin myopathies. Neuromuscul. Disord. 17, 355\u2013367 (2007).","journal-title":"Neuromuscul. Disord."},{"key":"775_CR208","unstructured":"Clinical Trials (Edgewise, accessed 2023); https:\/\/edgewisetx.com\/clinical-trials."},{"key":"775_CR209","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fgene.2018.00114","volume":"9","author":"G Cordova","year":"2018","unstructured":"Cordova, G., Negroni, E., Cabello-Verrugio, C., Mouly, V. & Trollet, C. Combined therapies for Duchenne muscular dystrophy to optimize treatment efficacy. Front. Genet. 9, 114 (2018).","journal-title":"Front. Genet."},{"key":"775_CR210","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/hum.2011.127","volume":"23","author":"IEC Verhaart","year":"2012","unstructured":"Verhaart, I. E. C. et al. Prednisolone treatment does not interfere with 2\u2019-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. Hum. Gene Ther. 23, 262\u2013273 (2012).","journal-title":"Hum. Gene Ther."},{"key":"775_CR211","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/hmg\/ddw201","volume":"25","author":"C Peccate","year":"2016","unstructured":"Peccate, C. et al. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. Hum. Mol. Genet. 25, 3555\u20133563 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR212","doi-asserted-by":"publisher","first-page":"164ra160","DOI":"10.1126\/scitranslmed.3005054","volume":"4","author":"GC Kendall","year":"2012","unstructured":"Kendall, G. C. et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci. Transl. Med. 4, 164ra160 (2012).","journal-title":"Sci. Transl. Med."},{"key":"775_CR213","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.omtn.2022.11.017","volume":"30","author":"F Bizot","year":"2022","unstructured":"Bizot, F. et al. Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice. Mol. Ther. Nucleic Acids 30, 606\u2013620 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"775_CR214","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1093\/hmg\/ddz049","volume":"28","author":"S Guiraud","year":"2019","unstructured":"Guiraud, S. et al. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy. Hum. Mol. Genet. 28, 2189\u20132200 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR215","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.omtm.2020.11.003","volume":"20","author":"H Hayashita-Kinoh","year":"2021","unstructured":"Hayashita-Kinoh, H. et al. Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment. Mol. Ther. Methods Clin. Dev. 20, 133\u2013141 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"775_CR216","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-319-22380-3_2","volume":"887","author":"TC Roberts","year":"2015","unstructured":"Roberts, T. C. The microRNA machinery. Adv. Exp. Med. Biol. 887, 15\u201330 (2015).","journal-title":"Adv. Exp. Med. Biol."},{"key":"775_CR217","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1096\/fj.08-128579","volume":"23","author":"S Greco","year":"2009","unstructured":"Greco, S. et al. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 23, 3335\u20133346 (2009).","journal-title":"FASEB J."},{"key":"775_CR218","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1038\/mtna.2012.26","volume":"1","author":"TC Roberts","year":"2012","unstructured":"Roberts, T. C. et al. Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol. Ther. Nucleic Acids 1, e39 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"775_CR219","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/embor.2010.208","volume":"12","author":"D Cacchiarelli","year":"2011","unstructured":"Cacchiarelli, D. et al. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep. 12, 136\u2013141 (2011).","journal-title":"EMBO Rep."},{"key":"775_CR220","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.celrep.2015.07.066","volume":"12","author":"AA Fiorillo","year":"2015","unstructured":"Fiorillo, A. A. et al. TNF-\u03b1-induced microRNAs control dystrophin expression in becker muscular dystrophy. Cell Rep. 12, 1678\u20131690 (2015).","journal-title":"Cell Rep."},{"key":"775_CR221","doi-asserted-by":"publisher","first-page":"e29376","DOI":"10.1371\/journal.pone.0029376","volume":"6","author":"U Basu","year":"2011","unstructured":"Basu, U. et al. Translational regulation of utrophin by miRNAs. PLoS ONE 6, e29376 (2011).","journal-title":"PLoS ONE"},{"key":"775_CR222","doi-asserted-by":"publisher","first-page":"e0182676","DOI":"10.1371\/journal.pone.0182676","volume":"12","author":"MK Mishra","year":"2017","unstructured":"Mishra, M. K., Loro, E., Sengupta, K., Wilton, S. D. & Khurana, T. S. Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction. PLoS ONE 12, e0182676 (2017).","journal-title":"PLoS ONE"},{"key":"775_CR223","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ymthe.2005.04.001","volume":"12","author":"S Abmayr","year":"2005","unstructured":"Abmayr, S., Gregorevic, P., Allen, J. M. & Chamberlain, J. S. Phenotypic improvement of dystrophic muscles by rAAV\/microdystrophin vectors is augmented by Igf1 codelivery. Mol. Ther. 12, 441\u2013450 (2005).","journal-title":"Mol. Ther."},{"key":"775_CR224","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/mt.2009.322","volume":"18","author":"J Dumonceaux","year":"2010","unstructured":"Dumonceaux, J. et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol. Ther. 18, 881\u2013887 (2010).","journal-title":"Mol. Ther."},{"key":"775_CR225","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1038\/mtna.2012.54","volume":"1","author":"A Malerba","year":"2012","unstructured":"Malerba, A. et al. Dual myostatin and dystrophin exon skipping by morpholino nucleic acid oligomers conjugated to a cell-penetrating peptide is a promising therapeutic strategy for the treatment of Duchenne muscular dystrophy. Mol. Ther. Nucleic Acids 1, e62 (2012).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"775_CR226","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1093\/hmg\/ddt342","volume":"22","author":"LR Rodino-Klapac","year":"2013","unstructured":"Rodino-Klapac, L. R. et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum. Mol. Genet. 22, 4929\u20134937 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR227","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01486-4","volume":"8","author":"V Mariot","year":"2017","unstructured":"Mariot, V. et al. Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat. Commun. 8, 1859 (2017).","journal-title":"Nat. Commun."},{"key":"775_CR228","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","volume":"24","author":"C Godfrey","year":"2015","unstructured":"Godfrey, C. et al. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum. Mol. Genet. 24, 4225\u20134237 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"775_CR229","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/jnnp-2013-306350","volume":"85","author":"JC van den Bergen","year":"2014","unstructured":"van den Bergen, J. C. et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J. Neurol. Neurosurg. Psychiatry 85, 747\u2013753 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"775_CR230","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1212\/WNL.39.8.1011","volume":"39","author":"EP Hoffman","year":"1989","unstructured":"Hoffman, E. P. et al. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 39, 1011\u20131017 (1989).","journal-title":"Neurology"},{"key":"775_CR231","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/jcsm.12506","volume":"11","author":"TLE van Westering","year":"2020","unstructured":"van Westering, T. L. E. et al. Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. J. Cachexia Sarcopenia Muscle 11, 578\u2013593 (2020).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"775_CR232","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.omtn.2022.08.033","volume":"29","author":"K Chwalenia","year":"2022","unstructured":"Chwalenia, K. et al. Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties. Mol. Ther. Nucleic Acids 29, 955\u2013968 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"775_CR233","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2147\/TCRM.S172291","volume":"15","author":"T Dangouloff","year":"2019","unstructured":"Dangouloff, T. & Servais, L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther. Clin. Risk Manag. 15, 1153\u20131161 (2019).","journal-title":"Ther. Clin. Risk Manag."},{"key":"775_CR234","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mus.27532","volume":"66","author":"S Thomas","year":"2022","unstructured":"Thomas, S. et al. Time to diagnosis of Duchenne muscular dystrophy remains unchanged: findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000-2015. Muscle Nerve 66, 193\u2013197 (2022).","journal-title":"Muscle Nerve"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00775-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00775-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T18:39:29Z","timestamp":1703097569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-023-00775-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":234,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1038\/s41573-023-00775-6","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"28 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.E.D. is a member of the scientific advisory board of Sarepta Therapeutics. M.J.A.W. is an adviser and shareholder in PepGen Ltd and Evox Therapeutics. T.C.R. declares no financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}